A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer

Completed · Phase 2

Conditions studied: Prostatic Neoplasms, Metastases, Neoplasm

In brief

The primary purpose of this study is to determine the safest dose of ZD4054 (Zibotentan)in men with prostate cancer

Key facts

Study ID

NCT00055471

Run by

AstraZeneca

People needed

22

Starts

2003-06-01

Expected to finish

2005-10-01

Last updated by the study team

2012-10-31

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Men 18 years \& older
• Confirmed diagnosis of prostate cancer with bone metastases

You may not qualify if…

• No more than 2 prior chemotherapy regimens
• No radiation, chemotherapy or bisphosphonates in the past 4 weeks

Where it is running

• Research Site — Cleveland, Ohio, United States
• Research Site — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.